IBDEI11O ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16791,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16791,1,3,0)
 ;;=3^Viral Agent Cause of Disease
 ;;^UTILITY(U,$J,358.3,16791,1,4,0)
 ;;=4^B97.89
 ;;^UTILITY(U,$J,358.3,16791,2)
 ;;=^5000879
 ;;^UTILITY(U,$J,358.3,16792,0)
 ;;=B97.10^^88^881^21
 ;;^UTILITY(U,$J,358.3,16792,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16792,1,3,0)
 ;;=3^Enterovirus Cause of Disease
 ;;^UTILITY(U,$J,358.3,16792,1,4,0)
 ;;=4^B97.10
 ;;^UTILITY(U,$J,358.3,16792,2)
 ;;=^5000861
 ;;^UTILITY(U,$J,358.3,16793,0)
 ;;=B34.9^^88^881^90
 ;;^UTILITY(U,$J,358.3,16793,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16793,1,3,0)
 ;;=3^Viral Infection,Unspec
 ;;^UTILITY(U,$J,358.3,16793,1,4,0)
 ;;=4^B34.9
 ;;^UTILITY(U,$J,358.3,16793,2)
 ;;=^5000603
 ;;^UTILITY(U,$J,358.3,16794,0)
 ;;=A69.20^^88^881^50
 ;;^UTILITY(U,$J,358.3,16794,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16794,1,3,0)
 ;;=3^Lyme Disease,Unspec
 ;;^UTILITY(U,$J,358.3,16794,1,4,0)
 ;;=4^A69.20
 ;;^UTILITY(U,$J,358.3,16794,2)
 ;;=^5000375
 ;;^UTILITY(U,$J,358.3,16795,0)
 ;;=A69.22^^88^881^52
 ;;^UTILITY(U,$J,358.3,16795,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16795,1,3,0)
 ;;=3^Neurologic Disorders d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,16795,1,4,0)
 ;;=4^A69.22
 ;;^UTILITY(U,$J,358.3,16795,2)
 ;;=^5000377
 ;;^UTILITY(U,$J,358.3,16796,0)
 ;;=A69.21^^88^881^51
 ;;^UTILITY(U,$J,358.3,16796,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16796,1,3,0)
 ;;=3^Meningitis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,16796,1,4,0)
 ;;=4^A69.21
 ;;^UTILITY(U,$J,358.3,16796,2)
 ;;=^5000376
 ;;^UTILITY(U,$J,358.3,16797,0)
 ;;=A69.29^^88^881^18
 ;;^UTILITY(U,$J,358.3,16797,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16797,1,3,0)
 ;;=3^Conditions d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,16797,1,4,0)
 ;;=4^A69.29
 ;;^UTILITY(U,$J,358.3,16797,2)
 ;;=^5000379
 ;;^UTILITY(U,$J,358.3,16798,0)
 ;;=A69.23^^88^881^5
 ;;^UTILITY(U,$J,358.3,16798,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16798,1,3,0)
 ;;=3^Arthritis d/t Lyme Disease
 ;;^UTILITY(U,$J,358.3,16798,1,4,0)
 ;;=4^A69.23
 ;;^UTILITY(U,$J,358.3,16798,2)
 ;;=^5000378
 ;;^UTILITY(U,$J,358.3,16799,0)
 ;;=A51.0^^88^881^29
 ;;^UTILITY(U,$J,358.3,16799,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16799,1,3,0)
 ;;=3^Genital Syphilis,Primary
 ;;^UTILITY(U,$J,358.3,16799,1,4,0)
 ;;=4^A51.0
 ;;^UTILITY(U,$J,358.3,16799,2)
 ;;=^5000272
 ;;^UTILITY(U,$J,358.3,16800,0)
 ;;=A52.3^^88^881^54
 ;;^UTILITY(U,$J,358.3,16800,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16800,1,3,0)
 ;;=3^Neurosyphilis,Unspec
 ;;^UTILITY(U,$J,358.3,16800,1,4,0)
 ;;=4^A52.3
 ;;^UTILITY(U,$J,358.3,16800,2)
 ;;=^5000298
 ;;^UTILITY(U,$J,358.3,16801,0)
 ;;=A52.10^^88^881^53
 ;;^UTILITY(U,$J,358.3,16801,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16801,1,3,0)
 ;;=3^Neurosyphilis Symptomatic,Unspec
 ;;^UTILITY(U,$J,358.3,16801,1,4,0)
 ;;=4^A52.10
 ;;^UTILITY(U,$J,358.3,16801,2)
 ;;=^5000291
 ;;^UTILITY(U,$J,358.3,16802,0)
 ;;=A52.9^^88^881^49
 ;;^UTILITY(U,$J,358.3,16802,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16802,1,3,0)
 ;;=3^Late Syphilis,Unspec
 ;;^UTILITY(U,$J,358.3,16802,1,4,0)
 ;;=4^A52.9
 ;;^UTILITY(U,$J,358.3,16802,2)
 ;;=^5000308
 ;;^UTILITY(U,$J,358.3,16803,0)
 ;;=A53.9^^88^881^79
 ;;^UTILITY(U,$J,358.3,16803,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16803,1,3,0)
 ;;=3^Syphilis,Unspec
 ;;^UTILITY(U,$J,358.3,16803,1,4,0)
 ;;=4^A53.9
